0
0
5/11/23 at 6:00am
Organization
FDA.gov
Author
Office of the Commissioner
41 words
0
Comments
The FDA granted supplemental approval to Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease
You are the first to view
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease
Create an account
or login to join the discussion